These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 7880189)

  • 1. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial.
    Furst DE; Clements PJ; Wong WK; Mayes MD; Wigley F; White B; Weisman M; Barr W; Moreland L; Martin R; Medsger TA; Steen V; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Peter JB; Seibold JR
    Rheumatology (Oxford); 2001 Jun; 40(6):615-22. PubMed ID: 11426017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Trial Design Issues in Systemic Sclerosis: an Update.
    Gordon JK; Domsic RT
    Curr Rheumatol Rep; 2016 Jun; 18(6):38. PubMed ID: 27146381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.
    Villela R; Yuen SY; Pope JE; Baron M;
    Arthritis Rheum; 2008 May; 59(5):706-13. PubMed ID: 18438906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Chung MP; Chung L
    Expert Opin Investig Drugs; 2020 Apr; 29(4):349-362. PubMed ID: 32178544
    [No Abstract]   [Full Text] [Related]  

  • 7. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis.
    Zulian F; Woo P; Athreya BH; Laxer RM; Medsger TA; Lehman TJ; Cerinic MM; Martini G; Ravelli A; Russo R; Cuttica R; de Oliveira SK; Denton CP; Cozzi F; Foeldvari I; Ruperto N
    Arthritis Rheum; 2007 Mar; 57(2):203-12. PubMed ID: 17330294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index.
    Khanna D
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5(Suppl 5):v31-2. PubMed ID: 18784137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition.
    Maddison P
    Rheumatology (Oxford); 2002 Sep; 41(9):965-71. PubMed ID: 12209028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in systemic sclerosis trial design.
    Denton CP
    Semin Arthritis Rheum; 2019 Dec; 49(3S):S3-S7. PubMed ID: 31779848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.
    van den Hombergh WMT; Kersten BE; Knaapen-Hans HKA; Thurlings RM; van der Kraan PM; van den Hoogen FHJ; Fransen J; Vonk MC
    Trials; 2018 Aug; 19(1):449. PubMed ID: 30134971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of skin involvement in systemic sclerosis.
    Kumánovics G; Péntek M; Bae S; Opris D; Khanna D; Furst DE; Czirják L
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v53-v66. PubMed ID: 28992173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials in systemic sclerosis: lessons learned and outcomes.
    Matucci-Cerinic M; Steen VD; Furst DE; Seibold JR
    Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S7. PubMed ID: 17767745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
    Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
    Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.
    Pellar RE; Pope JE
    Semin Arthritis Rheum; 2017 Jun; 46(6):767-774. PubMed ID: 28088339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial design in scleroderma: where are we and where do we go next?
    Chung L; Denton CP; Distler O; Furst DE; Khanna D; Merkel PA;
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S97-102. PubMed ID: 22691217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.
    Clements PJ; Seibold JR; Furst DE; Mayes M; White B; Wigley F; Weisman MD; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Wong WK
    Semin Arthritis Rheum; 2004 Feb; 33(4):249-63. PubMed ID: 14978663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and quality considerations for randomized controlled trials in systemic sclerosis.
    Kyriakidi M; Ioannidis JP
    Arthritis Rheum; 2002 Feb; 47(1):73-81. PubMed ID: 11932881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe organ involvement in systemic sclerosis with diffuse scleroderma.
    Steen VD; Medsger TA
    Arthritis Rheum; 2000 Nov; 43(11):2437-44. PubMed ID: 11083266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.